CAR-T Immunotherapy Targeting CD19- ALL

Abstract

This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers. Phase: PHASE1, PHASE2 Status: RECRUITING Conditions: B-cell Leukemia Interventions: 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR

Keywords

Sources